Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies 1st Edition by Margie Patlak, Jonathan Phillips, Sharyl J Nass ISBN 030936857X 9780309368575

Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies 1st Edition by Margie Patlak, Jonathan Phillips, Sharyl J Nass – Ebook PDF Instant Download/Delivery: 030936857X ,9780309368575
Full download Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies 1st Edition after payment

Product details:

ISBN 10: 030936857X
ISBN 13: 9780309368575
Author: Margie Patlak, Jonathan Phillips, Sharyl J Nass

A long-held goal in oncology has been to develop therapies that target the specific abnormalities in each patient’s cancer rather than simply treating cancers based on the tissue of origin. In the past decade, advances in technology have enabled researchers to relatively quickly and inexpensively determine, in minute detail, the genetic makeup of tumors. Although relatively few targeted cancer therapies are currently available in the clinic and it is not yet clear whether all cancers are driven by genetic changes that can be targeted, there is widespread optimism in the cancer community that this new ability to assess the genetic abnormalities in tumors will ultimately lead to better cancer treatments and improved patient outcomes.

Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies is the summary of a workshop convened in November 2014 by the Institute of Medicine’s National Cancer Policy Forum to discuss recent trends in the development and implementation of molecularly targeted cancer therapies and explore potential policy actions to address specific challenges. This report highlights the presentations and discussions at the workshop.

Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies 1st Edition Table of contents:

Workshop Summary (Chapters 1–6)

1. Introduction

2. Recent Advances in Tumor Biomarker Tests & Associated Challenges

3. Regulatory Oversight: FDA & Laboratory-Developed Tests (LDTs)

4. Evidence Standards, Trial Designs & Reimbursement Considerations

5. Clinical Practice Guidelines & Implementation Pathways

6. Education, Data Sharing & Research Infrastructure Needs

Appendix

• Workshop Statement of Task and Agenda

(Page numbering: Front Matter i–xx, Summary 1–80, Appendix 81–86) 

📋 In Summary:

• The Front Matter sets the context and defines the workshop’s scope.

• Chapters 1–6 present the core discussions on scientific, regulatory, economic, and implementation frameworks for biomarker-driven cancer therapies.

• The Appendix provides supporting logistics like the full agenda and task statement.

People also search for Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies 1st Edition:

behavioral issues in adopted child
    
current issues in adoption
    
core issues in adoption
    
challenges to policy implementation for adaptation
    
adoption of policy

Tags: Margie Patlak, Jonathan Phillips, Sharyl J Nass, Policy Issues, Development, Biomarkers, Molecularly Targeted